Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report)'s stock price was down 4.8% during trading on Monday . The company traded as low as $21.50 and last traded at $21.83. Approximately 224,694 shares changed hands during mid-day trading, an increase of 348% from the average daily volume of 50,104 shares. The stock had previously closed at $22.92.
Neoleukin Therapeutics Stock Performance
The firm has a market cap of $191.72 million, a PE ratio of -6.56 and a beta of 1.11. The firm has a fifty day simple moving average of $15.34 and a two-hundred day simple moving average of $17.64.
About Neoleukin Therapeutics
(
Get Free Report)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Recommended Stories
Before you consider Neoleukin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.
While Neoleukin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
